



Rheumatology

Syndicated Thought Leader Insight

Thought Leader Insight & Analysis Report

Rheumatology Q3 2011

Therapeutic Class:	Autoimmune Disorders
Focus Area:	Rheumatology
Specialty/Location:	Rheumatologists/N. America, Europe
Number of Interviews:	8
Number of Pages:	149
Publication Date:	October 2011
Principal Authors:	Kim Grant Tricia L. Hanlon Jeffrey D. Berk, Ph.D., MBA
Product Code:	MAIRQ311-33
Pricing:	\$7,500
Order Info:	www.medpredict.com or call (513) 271-1924

Abstract:

Rheumatology Thought Leader Panel #33 is a thought exercise conducted with eight North American (n=5) and European (n=3) rheumatologists in September 2011. We cover a broad range of rheumatologic conditions, with each Panelist having specific areas of specialization: rheumatoid arthritis, psoriatic arthritis, lupus, osteoporosis, gout, osteoarthritis. In this report we share each Panelist's "Fantasy Formulary", and the strengths, weaknesses and product news for each pharmacotherapy that is mentioned. The purpose of this exercise was to identify their "must have" branded and generic drugs for their real-world practice in the year 2016. This is the second time we've run this exercise, and we compare the current responses with a similar 8-Thought Leader cohort that we moderated in the spring of 2009.

Table of Contents

EXECUTIVE SUMMARY 4

Introduction 4

Methods..... 4

Results 7

Table 1*: 2011 Composite Scores by Drug Class.....	7
Table 2: 2011 Composite Scores for all Drugs Mentioned.....	8
Table 3: Top Ten Drugs (2009).....	9
Table 4: European Panelist Responses 2011.....	10
Table 5: European Panelist Responses 2009.....	10
Table 6: North American Panel Responses 2011.....	11
Table 7: North American Panel Responses 2009.....	11

Discussion - Preferred Classes 12

JAK.....	12
B-cell.....	12
Lupus.....	12
IL6.....	15
IL17.....	15

PANEL FAVORITES 16

JAK.....	16
tofacitinib (Pfizer).....	16
INCB-28050 (Incyte / Lilly).....	23
VX-509 (Vertex).....	24
B-Cell.....	25
Benlysta (belimumab; GSK / HGS).....	25
epratuzumab (UCB).....	28
atacept (Merck-Serono / ZymoGenetics).....	30
blisibimod (AMG-623; Anthera).....	32
Arzerra (ofatumumab; GlaxoSmithKline / Genmab).....	33
PCI-32765 (Pharmacocyclics).....	35
tabalumab LY2127399 (Lilly).....	36
IL6.....	38
Actemra/RoActemra (tocilizumab; Chugai / Roche).....	38
ALD-518/ BMS-945429 (BMS / Alder).....	43
sirukumab (Johnson & Johnson).....	44
olokizumab/CDP-6038 (UCB).....	44
Other IL-6 (sarilumab/Sanofi-Aventis / Regeneron).....	45
IL17.....	45
IL17 (AIN-457/secukinumab/Novartis; ixekizumab / Lilly, AMG-827/Amgen).....	45
Syk.....	49
fostamatinib (AstraZeneca / Rigel).....	49
Antiresorptive / RANKL.....	52
odanacatib (Merck).....	52

Prolia; denosumab (Amgen)	53
TNF.....	54
Biosimilar TNF	54
TNF-K-003 TNF-alpha kinoid vaccination (Neovacs)	59
CTLA4	60
Orencia (abatacept; BMS)	60
URAT1	63
lesinurad (RDEA-594; Ardea).....	63
Xanthine Oxidase.....	64
Bone Anabolic.....	65
AMG-785 (Amgen / UCB)	65
38A BMP-7 (Stryker).....	66
IFN α	66
Rontalizumab (Genentech)	66
sifalimumab (MEDI-545; Medimmune)	68
IL1	68
Arcalyst; rilonacept (Regeneron)	68
Ilaris; canakinumab (Novartis)	69
IL23	69
Stelara (ustekinumab; Centocor)	70
Steroid	71
Lodotra (modified-release prednisone; Nitec).....	71
C5A	71
MP-435 (Mitsubishi Tanabe).....	71
Proteasome Inhibition	72
bortezomib(Millennium), carfilzomib (Onyx).....	72
GM-CSF	73
Regulatory T-Cell	74
BT-061 (Abbott / Biotest).....	74

THOUGHT LEADER INTERVIEWS 76

Interview BJE02594	76
Interview BJE02595	86
Interview BJE02596	97
Interview BJE02597	107
Interview BJE02598	118
Interview BJE02599	128
Interview BJE02601	139